6 completed, 2 recruiting, 2 terminated, 2 withdrawn. 14 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 14 | Completed 6, Recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease | Early Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 5 | 2026-09-30 | 2026-05-15 |
| CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease | Early Phase 1 | Recruiting | CorrectSequence Therapeutics Co., Ltd | 5 | 2024-09-02 | 2026-02-10 |
| Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling Biotin-labeled red blood cells - Sickle Cell Disease, Thalassemia | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 100 | 2024-05-17 | 2026-09-28 |
| Alternative Dosing And Prevention of Transfusions (ADAPT) Hydroxyurea - Sickle Cell Disease | Early Phase 1 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 100 | 2022-06-16 | 2026-04-09 |
| Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease Biotin label - Sickle Cell Disease, Sickle Cell Anemia | Early Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 22 | 2021-04-19 | 2024-02-13 |
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| RHD Genotype Matched Red Cells for Anti-D D+ RH genotype matched red cell units for transfusion - Sickle Cell Disease, Anti-D Antibodies | Early Phase 1 | Completed | Children's Hospital of Philadelphia | 5 | 2020-07-08 | 2025-05-02 |
| A Dose-Finding Study of AG-348 in Sickle Cell Disease AG-348 - Sickle Cell Disease | Early Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 17 | 2019-07-11 | 2022-07-12 |
| Stem Cell Transplant in Patients With Severe Sickle Cell Disease Alemtuzumab, Total Body Irradiation, Sirolimus - Sickle Cell Disease | Early Phase 1 | Terminated | Kathleen Dorritie | 1 | 2018-03-29 | 2022-06-28 |
| Fetal Hemoglobin Induction Treatment Metformin Metformin, Questionnaires - Sickle Cell Anemia, Sickle Cell Disease | Early Phase 1 | Completed | Baylor College of Medicine | 37 | 2017-03-02 | 2023-10-12 |
| Androgen Regulation of Priapism in Sickle Cell Disease Transdermal Androgel - Priapism, Sickle Cell Disease | Early Phase 1 | Withdrawn | Johns Hopkins University | 2014-03-01 | 2017-01-19 | |
| Novel Dose Escalation to Predict Treatment With Hydroxyurea Hydroxyurea - Sickle Cell Disease | Early Phase 1 | Completed | Baylor College of Medicine | 70 | 2013-10-01 | 2020-11-18 |
| Losartan for Sickle Cell Kidney Disease Losartan - Sickle Cell Disease | Early Phase 1 | Completed | Emory University | 24 | 2012-12-01 | 2017-07-17 |
| SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease Alternative donor bone marrow and cord blood - Sickle Cell Disease | Early Phase 1 | Terminated | Emory University | 3 | 2006-01-01 | 2013-09-17 |
Anemia, Sickle Cell (14) · Hematologic Diseases (2) · Hemoglobinopathies (2) · Hypogonadism (1) · Kidney Diseases (1) · Priapism (1) · Sickle Cell Trait (1) · Thalassemia (1) · beta-Thalassemia (1)
Anemia (14) · Anemia, Hemolytic (14) · Anemia, Hemolytic, Congenital (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (14) · Hemic and Lymphatic Diseases (14) · Hematologic Diseases (12) · Hemoglobinopathies (12) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Male (1)
Hydroxyurea (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Blood Transfusion (1) · Bortezomib (1) · Busulfan (1) · CT-P10 (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Dexamethasone (1) · Hematopoietic Stem Cell Transplantation (1) · Losartan (1) · Metformin (1) · Mycophenolic Acid (1) · Plasma Exchange (1)
Baylor College of Medicine (2) · Emory University (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Children's Hospital Medical Center, Cincinnati (1) · Children's Hospital of Fudan University (1) · Children's Hospital of Philadelphia (1) · CorrectSequence Therapeutics Co., Ltd (1) · Johns Hopkins University (1) · Kathleen Dorritie (1) · M.D. Anderson Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1)
United States (10) · China (2) · Uganda (1)
John F Tisdale, M.D. (2) · Alex George, MD, PhD (1) · Ann Haight, M.D. (1) · Arthur L Burnett, MD, MBA (1) · Kathleen Dorritie, MD (1) · Kris M Mahadeo (1) · Marianne Yee, MD (1) · Russell Ware, MD, PhD (1) · Stella Chou, MD (1) · Swee Lay Thein, M.D. (1) · Titilope Fasipe, MD (1) · Xiaowen Zhai, M.D. (1) · Yongrong Lai, M.D. (1)
PMID 35576529, PMID 38181784, PMID 39172743, PMID 39265169, PMID 40222814, PMID 40441700, PMID 41809202, PMID 42376265, PMID 42705233
R01HL147879 (1)